Reaction Biology offers a comprehensive portfolio of animal-based services for testing of new anti-cancer and angiogenesis-modulating drugs. Our integrated platform includes services for all steps of the drug discovery process, supporting the development of your preclinical candidate pipeline.
Our state-of-the-art animal facility is located in Germany. We are working under GV-SOLAS and ISO9001 in regard to standards of animal welfare and code of practice.
Human xenograft tumor models are the most frequently used in vivo models for the evaluation of the therapeutic effects of novel anti-cancer drug candidates, including subcutaneous, subQperior, orthotopic, and metastasis models.
The In Vivo Hollow Fiber Model is an efficient and economic screening approach which is used for two purposes: (i) Select the compound with the best in vivo activity ("compound screening"), or (ii) identify a suitable tumor cell line for in vivo efficacy studies ("tumor model screening")